Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplantation (FMT) is a microbial therapy being investigated by Zhujiang Hospital for the treatment of metabolic disorders. In the SETOM clinical trial, the procedure involves the administration of 200ml of donor-derived fecal microbiota suspension via a nasointestinal tube to patients with Type 2 Diabetes Mellitus and obesity. The therapeutic rationale is based on the gut-organ axis, where the introduction of a healthy microbial ecosystem aims to correct dysbiosis, enhance the production of beneficial metabolites like short-chain fatty acids, and ultimately improve glycemic control and promote weight loss by modulating systemic inflammation and insulin signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fecal microbiota transplantation (Zhujiang Hospital).